Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a type of blood cancer called CLL or SLL and whose disease meets medical guidelines indicating treatment is needed.
• People in Group 1 (first-time treatment): Those who have not yet been treated AND have at least one higher-risk feature of their cancer (such as certain genetic changes or no prior treatment), OR are aged 65 or older.
• People in Group 2 (previously treated): Those whose cancer came back or stopped responding after at least one prior treatment.
• People aged 18 or older.
• People who are reasonably active and able to carry out daily activities (as assessed by a standard medical scale called ECOG, with a score of 0, 1, or 2).
• People whose kidneys and liver are working well enough, based on specific blood test results (confirm specific values with trial site).
• People with blood cell counts (white cells and platelets) above certain minimum levels, unless low counts are caused by the cancer itself (confirm details with trial site).
• Women who could become pregnant must have a negative pregnancy test within 7 days before starting the study drugs, and must agree to use effective contraception during the study and for a set period after the last dose of each study drug.
• Women who cannot become pregnant due to menopause (more than 1 year) or having had their tubes tied or uterus removed are also considered eligible.
• Men who are sexually active must agree to use highly effective contraception, including a condom, during the study and for a set period after the last dose of certain study drugs.
• People who have been free of other cancers for the past 2 years, with some exceptions — certain skin cancers or very early-stage cancers of the cervix or breast may still be eligible even if recently diagnosed or treated (confirm with trial site).
• People who are willing and able to provide written consent to participate.

Who may not be able to join:

• People who have previously been treated with a combination of the same two types of targeted drugs used in this trial (BTK inhibitor and BCL2 inhibitor together), if their cancer did not respond well or came back within 2 years of finishing that treatment.
• People who have had major surgery, radiation, chemotherapy, immunotherapy, or certain other treatments, or received a live vaccine, within the 3 weeks before starting the study (a shorter timeframe may apply in some cases — confirm with trial site).
• People with a history of severe allergic reactions to certain types of antibody-based medicines.
• People with an active, uncontrolled serious infection (such as a bacterial, viral, or fungal infection).
• People who have tested positive for HIV, due to possible interactions between HIV medications and the study drugs.
• People with an active hepatitis B infection, based on certain blood test results (some people with past hepatitis B exposure may still be eligible — confirm with trial site).
• People with active hepatitis C, confirmed by a specific blood test.
• People with an active, uncontrolled autoimmune condition affecting blood cells (such as the immune system attacking red blood cells or platelets) that requires higher doses of steroid treatment.
• People with serious heart conditions, including uncontrolled irregular heartbeat, heart failure, or a heart attack within the past 6 months, or certain other significant heart disease.
• People who are currently pregnant or breastfeeding.
• People currently taking the blood-thinning medication warfarin.
• People who have taken certain medications known to strongly affect how the body processes drugs (called strong CYP3A inhibitors or inducers) within 7 days before starting the study drugs.
• People who have consumed grapefruit, grapefruit juice, Seville oranges, or star fruit within 7 days before starting one of the study drugs (venetoclax).
• People with a known bleeding disorder, or who have had a stroke or bleeding in the brain within the past 6 months.
• People with a condition that prevents them from swallowing or absorbing oral medications properly.
• People with any other serious medical, psychiatric, or laboratory finding that the trial doctor believes could make participation unsafe or affect the study results.

Important: Always verify eligibility with the trial site directly before applying.